{"id":"https://openalex.org/W60011501","doi":null,"title":"Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.","display_name":"Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.","publication_year":1994,"publication_date":"1994-05-01","ids":{"openalex":"https://openalex.org/W60011501","mag":"60011501","pmid":"https://pubmed.ncbi.nlm.nih.gov/7923316"},"language":"en","primary_location":{"id":"pmid:7923316","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7923316","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical therapeutics","raw_type":"Clinical Trial"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109182790","display_name":"Harold D. Itskovitz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I181190671","display_name":"New York Medical College","ror":"https://ror.org/03dkvy735","country_code":"US","type":"education","lineage":["https://openalex.org/I181190671"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"H D Itskovitz","raw_affiliation_strings":["Department of Medicine, New York Medical College, Valhalla"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, New York Medical College, Valhalla","institution_ids":["https://openalex.org/I181190671"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5109182790"],"corresponding_institution_ids":["https://openalex.org/I181190671"],"apc_list":null,"apc_paid":null,"fwci":0.9052,"has_fulltext":false,"cited_by_count":35,"citation_normalized_percentile":{"value":0.73506046,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"16","issue":"3","first_page":"490","last_page":"504"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11839","display_name":"Hormonal Regulation and Hypertension","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12075","display_name":"Sodium Intake and Health","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2916","display_name":"Nutrition and Dietetics"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/terazosin","display_name":"terazosin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/alpha-1-adrenergic-blockers","display_name":"alpha-1 adrenergic blockers","score":0.9179999828338623},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.8569999933242798},{"id":"https://openalex.org/keywords/antihypertensive-efficacy","display_name":"antihypertensive efficacy","score":0.9039999842643738},{"id":"https://openalex.org/keywords/blood-pressure-reduction","display_name":"blood pressure reduction","score":0.8330000042915344},{"id":"https://openalex.org/keywords/serum-lipids","display_name":"serum lipids","score":0.8679999709129333},{"id":"https://openalex.org/keywords/cholesterol","display_name":"cholesterol","score":0.6320000290870667},{"id":"https://openalex.org/keywords/triglycerides","display_name":"triglycerides","score":0.9800000190734863},{"id":"https://openalex.org/keywords/ldl-cholesterol","display_name":"LDL cholesterol","score":0.8690000176429749},{"id":"https://openalex.org/keywords/hyperlipidemia","display_name":"hyperlipidemia","score":0.8019999861717224},{"id":"https://openalex.org/keywords/combination-antihypertensive-therapy","display_name":"combination antihypertensive therapy","score":0.9100000262260437},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.6779999732971191},{"id":"https://openalex.org/keywords/systolic-hypertension","display_name":"systolic hypertension","score":0.8299999833106995},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.578000009059906},{"id":"https://openalex.org/keywords/congestive-heart-failure","display_name":"congestive heart failure","score":0.777999997138977},{"id":"https://openalex.org/keywords/peripheral-arterial-disease","display_name":"peripheral arterial disease","score":0.6140000224113464},{"id":"https://openalex.org/keywords/kidney-failure","display_name":"renal failure","score":0.5509999990463257}],"concepts":[{"id":"https://openalex.org/C2776679619","wikidata":"https://www.wikidata.org/wiki/Q280786","display_name":"Terazosin","level":3,"score":0.9857872724533081},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9116455316543579},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.7490547895431519},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5073010325431824},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.48163074254989624},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4462137818336487},{"id":"https://openalex.org/C2780192228","wikidata":"https://www.wikidata.org/wiki/Q575890","display_name":"Antihypertensive drug","level":3,"score":0.4236519932746887},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41517090797424316},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.36293262243270874},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.34294408559799194},{"id":"https://openalex.org/C2777562237","wikidata":"https://www.wikidata.org/wiki/Q835051","display_name":"Hyperplasia","level":2,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000317","descriptor_name":"Adrenergic alpha-Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D008055","descriptor_name":"Lipids","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011224","descriptor_name":"Prazosin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D011224","descriptor_name":"Prazosin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D058668","descriptor_name":"Adrenergic alpha-1 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:7923316","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7923316","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical therapeutics","raw_type":"Clinical Trial"},{"id":"mag:60011501","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7923316","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2410043790","https://openalex.org/W2072152061","https://openalex.org/W2142799504","https://openalex.org/W2024470357","https://openalex.org/W2155989656","https://openalex.org/W2071807672","https://openalex.org/W2434321433","https://openalex.org/W2023847964","https://openalex.org/W2317025482","https://openalex.org/W2410140263"],"abstract_inverted_index":{"The":[0,273,343],"purpose":[1],"of":[2,10,28,34,49,135,149,185,188,194,230,270,307,332,340,368,377],"this":[3],"study":[4],"was":[5,127,203,262,299],"to":[6,62,74,113,141,181,205,337],"evaluate":[7],"the":[8,11,199,341,366],"effects":[9,253,328,347],"alpha":[12],"1-blocking":[13],"agent":[14,76],"terazosin":[15,63,71,158,261,369],"on":[16,254],"blood":[17,21,228,255,277],"pressure":[18],"(BP)":[19],"and":[20,44,68,95,133,171,217,236,298,325,334,353,360],"lipids":[22],"in":[23,72,88,121,129,163,198,227,243,264,276,330],"a":[24,118,305],"large,":[25],"variant":[26],"population":[27],"patients":[29,36,51,143,283,303,333],"with":[30,37,138,151,165,183,266,284,304],"hypertension.":[31,82,153],"A":[32],"total":[33,231],"16,917":[35],"hypertension":[38],"were":[39,60,258,280,348],"evaluated":[40],"at":[41],"2214":[42],"primary":[43],"community":[45],"care":[46],"facilities;":[47],"7808":[48],"these":[50,186],"had":[52,78,159,178],"not":[53,79,179],"been":[54],"treated":[55],"previously":[56],"for":[57,375],"hypertension;":[58],"3928":[59],"switched":[61],"from":[64],"another":[65],"antihypertensive":[66,125,161,189,271,296],"agent;":[67],"5181":[69],"received":[70],"addition":[73],"an":[75],"that":[77,157],"controlled":[80],"their":[81],"Terazosin":[83,222,293],"produced":[84,223],"highly":[85,224],"significant":[86,119,192,225],"reductions":[87,193,226,275],"systolic":[89,152],"(-18.2":[90],"+/-":[91,98],"0.2":[92],"mm":[93,100],"Hg)":[94,101],"diastolic":[96],"(-13.2":[97],"0.1":[99],"BP":[102,195],"when":[103,247,260],"used":[104,248,263],"as":[105,249,370],"monotherapy":[106,182,371],"(mean":[107],"dose,":[108],"3.1":[109,207],"mg;":[110,208,211,216],"range,":[111],"2":[112],"10":[114],"mg)":[115],"without":[116,241],"causing":[117],"increase":[120],"heart":[122,312],"rate.":[123],"Equal":[124],"efficacy":[126,162,297],"demonstrated":[128,259],"men,":[130],"women,":[131],"blacks,":[132],"whites":[134],"all":[136,267],"ages,":[137],"particular":[139],"benefit":[140],"elderly":[142],"(>":[144],"or":[145,289,372],"=":[146,290],"65":[147],"years":[148],"age)":[150],"Comparative":[154],"studies":[155],"indicated":[156],"equal":[160],"combination":[164,265],"diuretics,":[166,206],"beta-blockers,":[167,209],"calcium":[168,212],"channel":[169,213],"blockers,":[170,214],"angiotensin-converting":[172],"enzyme":[173],"(ACE)":[174],"inhibitors.":[175],"Patients":[176],"who":[177],"responded":[180],"one":[184],"classes":[187,269],"drugs":[190],"showed":[191],"after":[196],"terazosin,":[197],"following":[200],"average":[201],"doses,":[202],"added":[204],"3.4":[210,220],"3.3":[215],"ACE":[218],"inhibitors,":[219],"mg.":[221],"levels":[229,257],"cholesterol":[232,239,246,278,287],"(-5.0%),":[233],"triglycerides":[234],"(-6.1%),":[235],"low-density":[237],"lipoprotein":[238,245],"(-7.6%)":[240],"change":[242],"high-density":[244],"monotherapy.":[250],"Similar":[251],"favorable":[252],"lipid":[256],"other":[268],"drugs.":[272],"greatest":[274],"(-9.2%)":[279],"observed":[281],"among":[282],"hyperlipidemia":[285],"(total":[286],">":[288],"240":[291],"mg/dL).":[292],"maintained":[294],"its":[295],"well":[300],"tolerated":[301],"by":[302],"variety":[306],"concomitant":[308],"diseases,":[309],"including":[310],"congestive":[311],"failure,":[313],"peripheral":[314],"vascular":[315],"disease,":[316,320],"chronic":[317],"obstructive":[318],"pulmonary":[319],"benign":[321],"prostatic":[322],"hyperplasia,":[323],"diabetes,":[324],"obesity.":[326],"Adverse":[327],"occurred":[329],"17.9%":[331],"caused":[335],"2.2%":[336],"drop":[338],"out":[339],"study.":[342],"most":[344],"frequent":[345],"adverse":[346],"dizziness":[349],"(4.8%),":[350],"headache":[351],"(2.5%),":[352],"asthenia":[354],"(2.4%).":[355],"Only":[356],"0.4%":[357],"suffered":[358],"syncope":[359],"0.2%":[361],"impotence.":[362],"These":[363],"data":[364],"demonstrate":[365],"usefulness":[367],"add-on":[373],"therapy":[374],"treatment":[376],"hypertension.(ABSTRACT":[378],"TRUNCATED":[379],"AT":[380],"250":[381],"WORDS)":[382]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}